A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To offer an investigational agent (saquinavir) to people with HIV/AIDS who are in need of additional treatment options and are not eligible to enroll in ongoing clinical trials.
Patients who no longer benefit from existing antiretroviral therapy and who are not currently enrolled in ongoing saquinavir trials are eligible for this compassionate treatment program.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: Saquinavir | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | An Open Label International Compassionate Treatment Program for the Use of Saquinavir (R0 31-8959) Either As Monotherapy or in Combination With Other Anti-Retroviral Drugs in Patients With Proven HIV Infection |
| Estimated Enrollment: | 4000 |
Patients who no longer benefit from existing antiretroviral therapy and who are not currently enrolled in ongoing saquinavir trials are eligible for this compassionate treatment program.
Patients may be registered with the program through their physicians, who will be responsible for supervising the administration of treatment; following guidelines for saquinavir dose interruption, dose reduction, or discontinuation; and assessing patient progress throughout the duration of the study. Access to saquinavir will be determined by a lottery system; 60 percent of the program slots will be reserved for patients with CD4 counts of 50 or less and the remaining 40 percent of the slots will be devoted to patients with CD4 counts between 51 and 300.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 13 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
- Sero-positivity for HIV -1 antibody by an ELISA test, with confirmation by an alternative method.
- CD4 count <= 300 cells/mm3 (within 4 weeks prior to entry).
- Signed, informed consent from a parent or legal guardian for patients < 18 years of age.
- Failed previous therapy with or be intolerant to other registered anti-retroviral drugs.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Eligibility for any controlled clinical study of any experimental HIV therapy.
- Grade 4 hematologic and/or Grade 3 hematologic toxicity at baseline.
Patients with the following prior conditions are excluded:
Known hypersensitivity to saquinavir or other protease inhibitors. 1. Drugs, such as rifampin and rifabutin, which induce hepatic enzymes are likely to result in decreased levels of saquinavir and, therefore, should be avoided where possible.
- Concomitant therapy and treatment should be kept at a minimum.
-
Current participation in any study formally excluding concomitant treatment with experimental drugs.
1. Saquinavir can be used in combination with other registered anti-retroviral drugs such as ZDV, ddC and/or ddl. Other not yet registered anti-retroviral drugs can be used in combination with saquinavir when these drugs are widely available in the respective country or when they are allowed in combination treatment in any on-going clinical study.
- Prophylactic treatment for any opportunistic infections.
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002382
| United States, New Jersey | |
| Hoffmann - La Roche Inc | |
| Nutley, New Jersey, United States, 071101199 | |
More Information
| ClinicalTrials.gov Identifier: | NCT00002382 History of Changes |
| Other Study ID Numbers: |
229L SV14974 |
| First Submitted: | November 2, 1999 |
| First Posted: | August 31, 2001 |
| Last Update Posted: | December 9, 2005 |
| Last Verified: | June 1997 |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
Zalcitabine Didanosine Drug Therapy, Combination Zidovudine |
HIV Protease Inhibitors Saquinavir Patient Selection Anti-HIV Agents |
Additional relevant MeSH terms:
|
Infection HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
Saquinavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |